Nuvation Bio
Nuvation Bio is a biopharmaceutical company.
Launch date
Employees
Market cap
CAD1.4b
Enterprise valuation
CAD630m (Public information from Sep 2024)
Share price
$2.95 NUVB
New York City New York (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | 1.4m | <1m | 28.9m |
% growth | - | - | - | - | - | (53 %) | 4282 % |
EBITDA | (43.7m) | (97.3m) | (129m) | (100m) | - | - | - |
Profit | (41.7m) | (86.8m) | (104m) | (75.8m) | (544m) | (150m) | (197m) |
% profit margin | - | - | - | - | (38350 %) | (22781 %) | (681 %) |
EV / revenue | - | - | - | - | 566.0x | 1215.7x | 27.7x |
EV / EBITDA | -4.8x | -19.0x | -3.3x | -3.3x | - | - | - |
R&D budget | 32.6m | 69.0m | 87.8m | 71.3m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$275m | Series A | ||
N/A | N/A | IPO | |
$275m | Post IPO Equity | ||
Total Funding | CAD375m |
Related Content
Recent News about Nuvation Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Nuvation Bio
EditACQUISITION by Nuvation Bio Mar 2024